Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1617 1632 1648 1671 1672
This examiner grants 66% of resolved cases
Myron G. Hill serves in Tech Center 1600 and Art Unit 1617, where he has reached a resolution in 704 cases. His allowance rate of 66.2% provides a solid foundation for applicants seeking a grant. The median days to allowance is 1175, which sets a clear expectation for the length of the prosecution process. These metrics, based on 704 resolved cases, offer a reliable look at his examination style and the typical outcomes for applications on his docket.
The interview lift pct of 20.6% indicates that direct communication with the examiner is a beneficial strategy. This lift shows that an interview can meaningfully increase the 66.2% allowance rate. Given the 1175 median days to allowance, practitioners should consider an interview as a tool to not only improve the odds of success but also to potentially clarify issues that might otherwise prolong the process. The data from 704 resolved cases suggests that this 20.6% lift is a consistent trend in his practice.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18314980 | RESPIRATORY SYNCYTIAL VIRUS VACCINE | Non-Final OA | ModernaTX, Inc. |
| 18452524 | CONFORMATIONAL EPITOPES IN RESPIRATORY SYNCYTIAL VIRUS G PROTEIN CENTRAL CONSERVED REGION | Final Rejection | The Regents of the University of California |
| 18031294 | ADENO-ASSOCIATED VIRUS VIRIONS AND METHODS OF USE THEREOF | Final Rejection | The Regents of the University of California |
| 18655408 | POLYNUCLEOTIDES ENCODING NOROVIRUS VP1 ANTIGENS AND USES THEREOF | Non-Final OA | Merck Sharp & Dohme LLC |
| 17925966 | IMMUNOGENIC COMPOSITIONS AND USES THEREOF | Final Rejection | Flagship Pioneering Innovations VI, LLC |
| 18411568 | Ferritin Proteins | Final Rejection | SANOFI |
| 18558346 | COMPOSITIONS AND METHODS FOR DETECTING HUMAN ADENOVIRUS NUCLEIC ACID | Non-Final OA | Gen-Probe Incorporated |
| 18287139 | HUMAN ANTIBODY TARGETING COVID-19 VIRUS | Final Rejection | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 18282730 | METHODS AND COMPOSITIONS FOR HIGH-POTENCY POLYPEPTIDE-BASED PROTEIN INHIBITION | Non-Final OA | Baylor College of Medicine |
| 18799179 | CHIMERIC VECTORS | Non-Final OA | The United States of America, as represented by the Secretary, Department of Health and Human Servic |
| 18493936 | Methods of Treatment of High-Grade Squamous Intraepithelial Lesion (HSIL) | Non-Final OA | Inovio Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy